论文部分内容阅读
阿糖胞苷(AraC)是白血病治疗中最古老的药物之一,至今成人急性髓细胞白血病(AML)大部分治疗方案仍以其为基本组成。大剂量阿糖胞苷(HD-AraC)对难治、复发 AML 有明显的抗白血病活性,增加 AraC 剂量的联合方案已被作为一线治疗。前瞻性随机研究已证实诱导期或强化巩固期使用 HD-AraC 远期疗效佳,但相对于传统剂量(如100～200mg/m~2.次)AraC 最佳剂量多少为宜,目前仍未明了。药代动力学显示:短时间内注射 AraC 0.5～1.0g/m~2,细胞浆内可催化 AraC
Cytarabine (AraC) is one of the oldest drugs in the treatment of leukemia. So far, most of the treatment options for adult acute myeloid leukemia (AML) are still based on it. High-dose cytarabine (HD-AraC) on refractory, relapsed AML obvious anti-leukemia activity, increased dose of AraC combination of the program has been treated as a first-line treatment. Long-term prospective efficacy of HD-AraC during induction or intensive consolidation has been demonstrated in prospective randomized studies, but it is not clear what the optimal dose of AraC is for conventional doses (eg, 100-200 mg / m 2) . Pharmacokinetics showed: AraC 0.5 ~ 1.0g / m ~ 2 injection within a short time, the cytoplasm could catalyze AraC